Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drug use surveillance of Takecab tablets for "Gastric ulcer, duodenal ulcer, and reflux esophagitis"

Next Previous
Trial Profile

Drug use surveillance of Takecab tablets for "Gastric ulcer, duodenal ulcer, and reflux esophagitis"

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vonoprazan (Primary)
  • Indications Duodenal ulcer; Gastric ulcer; Reflux oesophagitis
  • Focus Adverse reactions
  • Sponsors Takeda

Most Recent Events

  • 06 Nov 2018 Status changed from active, no longer recruiting to completed.
  • 06 Sep 2018 Planned End Date changed from 30 Apr 2018 to 31 Oct 2018.
  • 06 Sep 2018 Planned primary completion date changed from 30 Apr 2018 to 31 Oct 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top